![]() ![]() Share your opinion and gain insight from other stock traders and investors. ![]() Its therapeutic approach is designed to take advantage of a cancer cells innate metabolic weaknesses to cause cancer cell death. (TYME) stock discussion in Yahoo Finance's forum. Tons of financial metrics for serious investors. Get 20 years of historical value charts for TYME stock and other companies. SM-88 is an oral investigational modified proprietary tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Tyme Technologies : Syros to Raise Approximately 190 Million Through Merger with TYME Tec. Get value charts for Tyme Technologies (TYME). TYME Technologies (tymeinc) / Twitter TYME Technologies tymeinc TYME (Nasdaq: TYME), an innovative biotechnology company leveraging novel and data-driven approaches to develop therapeutics for difficult to treat cancers. Tyme Technologies Stock analysis including Tyme Technologies investment evaluation, stock information, alerts, predictive tools such as market volatility and liquidity estimators and more. It is focused on developing its novel compound, SM-88 and its preclinical pipeline of novel CMBT programs. The Company is developing cancer metabolism-based therapies (CMBTs ) that are effective across a broad range of solid tumors and hematologic cancers.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |